New eye drops aim to halt keratoconus progression

NCT ID NCT07400952

Recruiting now Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether GLK-221 eye drops can safely slow the progression of keratoconus, a condition that thins and bulges the cornea. About 100 adults with keratoconus will use the drops twice daily for several months. The main goal is to see if the drops reduce the steepening of the cornea compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLK-221 ophthalmic solution (eye drops)
What this could lead to: If successful, this could provide a non-surgical treatment to slow or stop the progression of keratoconus, potentially reducing the need for corneal transplants.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not confirm effectiveness. The treatment may not slow the disease or could cause side effects like eye irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KERATOCONUS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Glaukos Clinical Study Site
RECRUITING

Westerville, Ohio, 43082, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.